Despite the treatment‐resistant nature of some patients, anti‐CGRP therapies continue to exhibit effectiveness, not only among individuals with refractory migraines but also in those with migraine and MO [12, 26, 27, 28]. The gene discussed is CALCA; the disease is migraine disorder.